



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034,
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

4th August, 2016

Corporate Relationship Department
M/s.BSE Limited
Dalal Street, Fort
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) **Mumbai 400 051**

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclose herewith the Press Release for your information.

Thanking you,

Yours faithfully,
For NATCO Pharma Limited

A handwritten signature in black ink, appearing to read "M. Adinarayana".

M.Adinarayana
Company Secretary &
Vice President (Legal & Corp. Affairs)



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034,
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref:PR/004/2016

Press Release

NATCO RECEIVES FINAL APPROVAL FOR GENERIC TAMIFLU®

Hyderabad, India, August 4th, 2016

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce final approval of Abbreviated New Drug Application (ANDA) containing a paragraph IV certification filed with the U.S. Food and Drug Administration (FDA) for generic versions of TAMIFLU® oral capsules (Roche's trade name for Oseltamivir Phosphate), 30 mg, 45 mg and 75 mg. NATCO and its marketing partner Alvogen are the first generic players to receive this approval.

Earlier in December, 2015, NATCO and Alvogen settled a patent infringement with Gilead Sciences, Inc., Hoffmann-La Roche Inc., F. Hoffmann-La Roche Ltd. and Genentech, Inc. Under the terms of the settlement, NATCO's partner Alvogen will be able to market the oseltamivir phosphate capsules before the expiration of the pediatric exclusivity period listed in FDA's Orange Book for U.S. Patent No. 5,763,483, which is February 23, 2017.

TAMIFLU® oral capsules had U.S. sales of approximately \$403 Million for twelve months ending December 2015, according to IMS Health.

Forwarded for favor of publication

For NATCO Pharma Limited

**M. Adinarayana
Company Secretary &
Vice President (Legal and Corp Affairs)**